01 December 2005
The antimicrobial potential of honey from United Arab Emirates on some microbial isolates.
Noori Al-Waili, Muhammad Akmal, Faiza Al-Waili, Khelod Saloom, Amjed AliMed Sci Monit 2005; 11(12): BR433-438 :: ID: 438827
Abstract
Background: The study investigated activity of honey towards pathogenswhen grown in media contained honey, or when honey was added to cultures after inoculation. Material/Methods:1 -Staphylococcus aureus (S. aureus), Streptococcus pyogenes (S. pyogenes), E.coli and Candida albicans(C. albicans) were cultured into broth containing 10-100% (wt/v) honey concentrations. 2 - Honey wasadded to broth inoculated with isolates after inoculation. 3 - Optimum growth of isolates, therapeuticperiod of honey, and time after addition of honey that showed optimum effect was measured. Results: Theoptimum growth of E. Coli and C. Albicans was 10 hrs and S. aureus was 12 hrs. Honey (30-70%) preventsgrowth of all isolates. Honey (80%) inhibited growth of small (1 ul) and large size of inoculum (10 ul)of E. Coli and S. Aureus when added to their cultures during 24 hrs after inoculation. Honey inhibitedgrowth of C. Albicans when added during 2 to 6 hrs after inoculation. Honey delayed the appearance ofmicrobial growth on the plates. Reculturing of specimens collected from media that showed no growth afteraddition of honey yielded recovery growth for E.coli and C. Albicans, and therapeutic period of honeyfor E.coli and S. Aureus was 2-24 hrs and for C. Albicans was 2-6 hrs. Conclusions: Honey prevents growthof the isolates and inhibits their growth when honey was added to growing culture. The therapeutic periodof honey and recovery growth of inhibited isolates necessitates adjustment of honey doses according totype of isolate and grade of growth.
Keywords: Culture Media - pharmacology, Candida albicans - growth & development, Anti-Infective Agents - pharmacology, Escherichia coli - growth & development, Honey, Staphylococcus aureus - growth & development, Streptococcus pyogenes - growth & development, United Arab Emirates
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952